Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical stage company, announced that it has dosed…